Dementia with Lewy bodies

Medical Clinics of North America

Volumn 86, Issue 3, 2002, Pages 519-535

  Leverenz, James B ^a,b,c   McKeith, Ian G ^d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL RESEARCH; COGNITION; DEMENTIA; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; GENETIC ANALYSIS; HUMAN; LEWY BODY; MOTOR PERFORMANCE; NEUROCHEMISTRY; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SYMPTOMATOLOGY;

COGNITION; HUMANS; MENTAL DISORDERS; PARKINSON DISEASE;

EID: 0036324049     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00012-3     Document Type: Review

References (97)

1. An essay on the shaking palsy
2. Senile trembing and paralysis agitans
3. Cinquieme lecon: De la paralysie agitante
4. De la paralysie agitante
5. Zur pathologischen anatomie der paralysis agitans
6. Les lesions anatomiques de la maladie de Parkinson
7. The brain-stem lesions in parkinsonism
8. Zur pathologie der paralysis agitans und des postenzephalitishen parkinsonismus
9. Parkinsonische krankheit (paralysis agitans) und postencephalitischer parkinsonismus
10. Report of the second dementia with Lewy body international workshop: Diagnosis and treatment. Consortium on dementia with Lewy bodies
11. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
12. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
13. Pathobiology of the Lewy body
14. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity
15. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
16. Synucleinopathies: Clinical and pathological implications
17. Concentric hyalin inclusion body formation in mental disease analysis of twenty-seven cases
18. Diffuse Lewy body disease in Japan
19. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion
20. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients
21. Parkinson's disease in patients with Alzheimer's disease
22. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
23. Antemortem diagnosis of diffuse Lewy body disease
24. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemisty of CA2-3 neurites specific to DLBD
25. Lewy body variant
26. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT)
27. Neuropsychological deficits associated with diffuse Lewy body disease
28. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies
29. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease
30. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia
31. Neuropsychiatric syndromes in neurodegenerative disease: Frequency and significance
32. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease
33. Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups
34. Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease
35. Dementia with Lewy bodies: Findings from an international multicentre study
36. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease
37. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: Rostrocaudal distribution
38. Alzheimer's disease and its Lewy body variant: A clinical analysis of postmortem verified cases
39. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
40. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: A clinicopathologic study
41. Research evaluation and prospective diagnosis of dementia with Lewy bodies
42. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample
43. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies
44. Prospective evaluation of diagnostic criteria for dementia with Lewy bodies
45. Dementia with Lewy bodies: Reliability and validity of clinical and pathologic criteria
46. Diagnosing Lewy body disease: Accuracy of clinical criteria in detecting Lewy body pathology
47. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia
48. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: Magnetic resonance imaging volumetric study
49. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: A pilot study
50. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia
51. The medial temporal lobe in dementia with Lewy bodies: A comparative study with Alzheimer's disease
52. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies
53. Occipital glucose metabolism in dementia with Lewy bodies with and without Parkinsonism: A study using positron emission tomography
54. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD
55. Dementia with Lewy bodies: A study of postsynaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography
56. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies
57. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies
58. Cholinesterase inhibitors. Comparing the options for mild-to-moderate dementia
59. Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density
60. Lewy-body dementia and responsiveness to cholinesterase inhibitors: A paradigm for heterogeneity of Alzheimer's disease?
61. Donepezil for dementia with Lewy bodies: A case study
62. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial
63. Dementia with Lewy bodies: Response of delirium-like features to donepezil
64. Donepezil for behavioural disorders associated with Lewy bodies: A case series
65. Lewy bodies and response to tacrine in Alzheimer's disease
66. Dementia with Lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms, and sleep
67. Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial
68. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study
69. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
70. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
71. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
72. Low-dose olanzapine for levodopa induced dyskinesias
73. Worsening of motor function in Parkinson's disease: A "typical" response to "atypical" antipsychotic medications
74. Dopaminomimetric psychosis in Parkinson's disease patients: Diagnosis and treatment
75. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
76. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry
77. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
78. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease
79. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies
80. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: Relation to Alzheimer's disease
81. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease
82. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies
83. Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies
84. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
85. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
86. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
87. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation
88. Axon pathology in Parkinson's disease and lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
89. Beta-synuclein inhibits alpha-synuclein aggregation. A possible role as an anti-parkinsonian factor
90. Parkin ubiquitinates the alpha-synublein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson's disease
91. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
92. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
93. Familial dementia with Lewy bodies (DLB)
94. Pharmacological treatments of dementia